2012 ACG ANNUAL SCIENTIFIC MEETING

Transcription

1 2012 ACG ANNUAL SCIENTIFIC MEETING Symposia Sessions, Special Lectures and Oral Abstract Presentations Program Description, Faculty Listing and Disclosure Information....vii Course Evaluation and CME Information.... xvi MONDAY MORNING, October 22, 2012 Jerome Marks Memorial Lecture Gastroenterology Then and Now Lawrence S. Friedman, MD, FACG Simultaneous Symposia 1A: IBD Debate To Stop or Not to Stop: Do We Continue Therapy Indefinitely? Moderator: David T. Rubin, MD, FACG Case Presentation (Clinical Vignette) David T. Rubin, MD, FACG There Is No End in Sight: Continue Therapy Forever? William J. Sandborn, MD, FACG Determine the role of long term immunosuppressive treatment in IBD patients in remission. Stop Therapy After Achieving Remission: Immunomodulator or Biologic or Both? Miguel D. Regueiro, MD, FACG Interpret safety and efficacy criteria for withdrawal of IBD therapy. Simultaneous Symposia 1B: All in on Ablation in Barrett s Esophagus Moderator: Kenneth K. Wang, MD, FACG Have the Odds Changed? Do New Results Influence Old Algorithms in Treatment of Non-Dysplastic Barrett s Esophagus? Nicholas J. Shaheen, MD, FACG Interpret the results of recent studies regarding cancer risk in Barrett s in terms of ablation. Betting on Ablation: How to Treat Barrett s Esophagus Like a Pro Prateek Sharma, MD, FACG Describe the advances in treatment techniques in Barrett s esophagus. Doubling Up on Barrett s Esophagus: How Disease Recurrence Influences Follow-up After Ablation Kenneth K. Wang, MD, FACG Assess the risk of recurrence of Barrett s esophagus i

2 MONDAY AFTERNOON, October 22, 2012 The American Journal of Gastroenterology Lecture Fecal Transplantation for Persistent C. difficile Infection Lawrence J. Brandt, MD, MACG Simultaneous Symposia 2A: Hepatitis C: Making Sense of the Treatment Landscape Moderator: Paul Y. Kwo, MD, FACG New Therapies: Treat Now and How, or Wait? Andrew J. Muir, MD, MHS Understand the developments and complexities in HCV therapy; apply treatment advances in patient care. HCV Special Populations Paul Y. Kwo, MD, FACG Assess the unmet need for therapies in special HCV populations. HCV Therapy: What Is on the Horizon? Mitchell L. Shiffman, MD, FACG Examine newer therapies on the horizon. Simultaneous Symposia 2B: Quality Improvement in CRC Screening with Colonoscopy in 2012 Moderator: Douglas K. Rex, MD, MACG How Do You Define Quality Colonoscopy for CRC Screening? Philip S. Schoenfeld, MD, MSEd, MScEpi, FACG Define quality indicators and quantitative thresholds for quality colonoscopy, including cecal intubation rate, adenoma detection rate, complication rate, and adherence to guideline recommendations and the impact of bowel preparation. How Can You Improve ADRs and Other Quality Indicators for Underperformers? Douglas K. Rex, MD, MACG Identify causes of interval CRC after colonoscopy and techniques to improve adenoma detection rates, including identification of sessile serrated adenoma, inadequate polypectomy, decreased effectiveness of colonoscopy to prevent right-sided CRC, and impact of MSI instability and CIMP mutations on interval cancers. The Bottom Line: How to Document Quality Indicators and the Impact on Reimbursement David A. Johnson, MD, FACG Assess the utility of GIQuIC to document quality indicators and review proposed CMS rules on reimbursement based on quality indicators. TUESDAY MORNING, October 23, 2012 J. Edward Berk Distinguished Lecture Is Gastric Secretion Still Relevant? Mark Feldman, MD, FACG Simultaneous Symposia 3A: IBS: Do Microbes Matter? Moderator: Lin Chang, MD, FACG Pathogenesis: Do Gut Microbes Play a Role? Yehuda Ringel, MD, FACG Describe the mechanisms whereby microbes may contribute to the pathogenesis of IBS. Antibiotics: What to Do After They Work Lin Chang, MD, FACG Identify the role of antibiotics in treating IBS and what to do if they improve symptoms. Probiotics: When, Which Ones and Why? Filippo Cremonini, MD, PhD, MSc Assess the evidence of the role of probiotics in the management of IBS. ii

3 Simultaneous Symposia 3B: Controversial Malpractice Issues in Clinical GI Moderator: Richard S. Bloomfeld, MD, FACG Interval CRC: One of the Malpractice Claims Most Feared by Gastroenterologists Douglas K. Rex, MD, MACG Identify impact of informed consent and endoscopy report documentation on malpractice claims for interval CRC and pitfalls that increase your liability. Complications of IBD Management: Common Errors and How to Avoid Them Asher Kornbluth, MD Discuss common issues in IBD management that lead to malpractice claims and techniques to minimize liability. Endoscopic Adverse Events: It Happens Eventually Is Informed Consent Enough? John Baillie, MB, ChB, FACG Review impact of informed consent and endoscopy report documentation on malpractice claims and the approach to post-complication care which minimizes liability. TUESDAY AFTERNOON, October 23, 2012 Emily Couric Memorial Lecture Optimizing the Diagnosis and Management of Patients with Hereditary Colorectal Cancer Carol A. Burke, MD, FACG Simultaneous Symposia 4A: Burning the Candle at Both Ends: Managing the IBD Extremes Moderator: David A. Schwartz, MD, FACG How to Approach the Patient with Mild Ileitis William J. Tremaine, MD, FACG Formulate treatment strategies for patients with mild Crohn s ileitis. Managing Severe IBD Not Responsive to Immunomodulators or Anti-TNFs: Thinking Outside the Box David G. Binion, MD Describe medical and surgical options for patients with refractory IBD. Difficult to Treat Anorectal Problems: Proctitis, Strictures and Fistulas David A. Schwartz, MD, FACG Develop an understanding of management of complicated anorectal IBD. Simultaneous Symposia 4B: On-call Endoscopic Emergencies: A Case-based Approach Moderator: Douglas G. Adler, MD, FACG GI Bleeding John R. Saltzman, MD, FACG Improve recognition of true endoscopic emergencies. ERCP Emergencies Christopher J. DiMaio, MD Identify timing of endoscopic intervention in patients with endoscopic GI emergencies. Foreign Bodies David A. Greenwald, MD, FACG Demonstrate techniques to treat GI emergencies. iii

4 WEDNESDAY MORNING, October 24, 2012 David Y. Graham Lecture Factitious Disease John Fordtran, MD, FACG Simultaneous Symposia 5A: Challenges with Liver Lesions Moderator: K. Rajender Reddy, MD, FACG How to Approach the Solid Incidentaloma K. Rajender Reddy, MD, FACG Appreciate the commonly encountered solid and cystic lesions in the liver. What to Do with the Cystic Incidentaloma Mark W. Russo, MD Distinguish benign from solid lesions in the liver. HCC: Screening and Diagnosis Richard K. Sterling, MD, FACG Identify the populations at risk for HCC, initiate appropriate screening strategies, and diagnose the malignancy. Simultaneous Symposia 5B: Why Isn t Colonoscopy More Effective at Preventing Right-sided CRC and What Can We Do to Improve? Moderator: Aasma Shaukat, MD, FACG Are We Really Missing Right-sided CRC or Is Something Else Going On? Douglas J. Robertson, MD, MPH Review research data about frequency of interval CRC in right side of colon, including the role of sessile serrated adenomas. How Can We Minimize Missed Polyps in the Right Side of the Colon? Michael B. Wallace, MD, MPH, FACG Discuss techniques to minimize missed polyps in the right side of the colon, including identification of sessile serrated adenomas, and techniques to teach under-performers. Do Some Right-sided CRCs Grow Rapidly and What Should We Do About This? Aasma Shaukat, MD, FACG Identify molecular markers, including CIMP and MSI, of rapidly growing right-sided CRC. iv

5 ORAL ABSTRACT PRESENTATIONS Monday, October 22, 2012 Abstract Title page 1. Statins and the Risk of Esophageal Cancer: A Systematic Review and Meta-analysis The Inpatient Mortality Rate for Upper Gastrointestinal Hemorrhage Is Decreasing in the United States: A Nationwide Analysis Over Two Decades 3. Severe Sprue-like Enteropathy Associated with Olmesartan Causative Agents, Clinical Features, and Outcomes of Idiosyncratic Drug Induced Liver Injury (DILI) in the Elderly: Results From the DILIN Prospective Study 5. Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial 6. POEM (PerOral Endoscopic Myotomy): Effective NOTES (Natural Orifice Transluminal Endoscopic Surgery) Accessible to the Gastroenterologist, 3 Year Experience at a U.S. Center 7. Mesalamine Granules 1500 mg Once Daily for 12 Weeks Provides Adequate Relief of IBS Symptoms in Irritable Bowel Syndrome with Diarrhea: Results from a Phase 2 Trial 8. Investigation of MicroRNA in Pancreatic Cystic Tumors (IMPACT) Study: Differential Expression Observed Among Pancreatic Cystic Neoplasms 9. Elevated Risk of Colorectal Cancer and Adenomas in Relatives of Patients with Colorectal Cancer: A Population-based Study in Utah 10. Clinical Outcomes of Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) for Large Flat Colorectal Polyps 11. Adenoma Detection Rates in Screening versus Surveillance Colonoscopies: Data from the New Hampshire Colonoscopy Registry 12. The Relationship Between Withdrawal Time and Intubation Time in Colonoscopy: Correlation with Adenoma Detection Rate (ADR) 13. The Administration of Hyoscine N-butyl Bromide During Colonoscopy Does Not Increase the Adenoma Detection: A Randomized, Double-Blind, Controlled Study 14. Risk of Colorectal Cancer after Diagnosis of Endometrial Cancers: A Population Based Study Infertility and Pregnancy Outcomes in Celiac Disease A New Model to Predict Survival in Patients with Refractory Celiac Disease (MRCD): Results from a Multinational Study 17. Duodenal Adenomas Are Strongly Associated with an Increased Risk for Colonic Neoplasia Evaluation of Eating Behaviors and Quality of Life in Pre-Adolescents at Risk for Obesity with and without Abdominal Pain Tuesday, October 23, 2012 Abstract Title page 19. Day-Before Administration of a Novel, Dual-Action, Low-Volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR II Study 20. A New, Rapid, Effective, Tolerable, and Safe Preparation Suitable for Colonoscopy at Any Time of the Day: A Multicenter Study 21. The Incidence of Hyponatremia with Two Commonly Prescribed Purgatives for Colonoscopy Polyethylene Glycol 3350 with Sports Drink (PEG-SD) Compared to Polyethylene Glycol with Electrolyte Solution (PEG-ELS) 22. Water Exchange Method Colonoscopy Provides Salvage Cleansing and Improves Bowel Preparation, Even in Patients Receiving a Split Dose Bowel Regimen 23. Magnetic Endoscope Imaging (Scopeguide) Elucidates the Mechanism of Action of the Pain-alleviating Impact of Water Exchange Colonoscopy Attenuation of Loop Formation 24. Continuous Nursing Care in GI Endoscopy Improves Nurse and Room Utilization and Decreases Patient Wait Time v

6 25. Validation of Novel Risk Score to Predict In-hospital Mortality and Length of Stay in Acute Upper Gastrointestinal Bleeding 26. Fully-Covered Self-Expandable Metal Stents are More Efficacious than Plastic Stents as First-line Therapy in Treating Extrahepatic Benign Biliary Strictures Following Liver Transplantation 27. Stent-associated Esophagorespiratory Fistulas (SERF): Prevalence and Risk Factors Resource Utilization, Mortality and Disease Severity Trends in Patients Hospitalized for Hepatitis C in the United States 29. Efficacy, Safety and UK Cost-Effectiveness in Treatment-Naïve Patients with F2 Fibrosis Treated with 186 Telaprevir (TVR; T) in Combination with Peginterferon (P) and Ribavirin (R) vs Peginterferon and Ribavirin Alone 30. Adherence to Quality Indicators in Patients with Liver Disease Is Not Sufficient to Reduce 30-day 187 Readmissions or Mortality 31. Correlation Between Advanced Liver Disease and the Use of Advanced Directives or Power of Attorney: 188 Who Will Make the Decisions When the Patient Cannot? 32. HLA-A11 Gene Loci is Strongly Predictive of Susceptibility to Severe Hepatic Steatosis in Patients with 188 Non-Alcoholic Fatty Liver Disease (NAFLD) 33. Ultrasonographic Evidence of Hepatic Steatosis in Individuals without Metabolic Syndrome Framingham Risk Score Predicts Severity of Fibrosis but Not Necro-Inflammation in Patients with 189 Non Alcoholic Steatohepatitis (NASH) 35. Predicting Cardiovascular Events after Liver Transplantation: Does Degree of Coronary Vessel Disease 190 Play a Role? 36. TD-1211 Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a 191 Phase 2b Study of Patients with Opioid-Induced Constipation (OIC) 37. Importance of Reporting Segmental Bowel Preparation Scores During Colonoscopy in Clinical Practice Real-time Feedback Improves the Quality of Colonoscopy by Trainees: A Controlled Clinical Trial Racial Differences in Refusal of Surgery for Colorectal Cancer in the United States The Epidemiology and Outcomes of Clostridium difficile Infection in Children from : 193 Results from a Nationwide Survey 41. Do Statins Protect against Clostridum difficile Associated Diarrhea? Vedolizumab Induction and Maintenance Therapy for Crohn s Disease: Results of Gemini II, Two 194 Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Trials 43. A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy 196 of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance 44. The Natural History of Systemic Corticosteroid Therapy in Ulcerative Colitis: A Nationwide, 196 Retrospective Cohort from the Veterans Affairs Healthcare System 45. Assessment of Therapy Changes and Drug Discontinuation among Ulcerative Colitis Patients using 197 Health Claims Data 46. Lower Esophageal Sphincter (LES) Electrical Stimulation Eliminates Proximal Esophageal Acid Exposure 198 in Patients with GERD 1 Year Results 47. The Prevalence of Eosinophilic Esophagitis in the United States Military Healthcare Population Prospective Determination of the Prevalence of PPI-responsive Esophageal Eosinophilia in Patients with 199 Dysphagia Undergoing Upper Endoscopy 49. Diabetes Mellitus Increases the Risk of Barrett s Esophagus: Results from a Large Population Based 200 Case Control Study 50. In Patients with Non-dysplastic Barrett s Esophagus (NDBE), Selective Endoscopic Ablative Therapy 201 (EAT) Based on Risk-stratification by Molecular Analysis of Mutational Load (ML) is the Most Cost- Effective Management Strategy 51. Prevalence of Comorbidities in a Racially Diverse Population with Irritable Bowel Syndrome: 201 Results of a Retrospective Cross-Sectional Study 52. Confocal Laser Endomicroscopy Findings of the Small Intestine in Irritable Bowel Syndrome (IBS) vi

7 Wednesday, October 24, 2012 Abstract Title page 55. Rectal NSAIDs Are More Effective than Pancreatic Stents in Preventing Post-ERCP Pancreatitis among High-Risk Patients: A Systematic Review and Network Meta-Analysis 56. First Use of PET/CT Using Fluorine-18 FDG-labeled Autologous Leucocytes in the Diagnosis of Infected Fluid Collections in Acute Pancreatitis 57. Alterations in Cross-sectional Imaging and Cyst Fluid Genetics Following Endoscopic Ultrasound Guided Pancreatic Cyst Ablation with Ethanol and Paclitaxel 58. Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound, Through-the-needle Confocal Laser-induced Endomicroscopy and Cystoscopy Trial (DETECT Study) 59. Susceptibility to Alcoholic Pancreatitis but Not Sporadic Pancreatitis Is Significantly Reduced by the IL23R R381Q Gene Variant 60. Pancreatitis Quality of Life Instrument (PANQOLI): A Psychometric Evaluation In vivo Diagnosis of Gastric Intestinal Metaplasia Using Probe-Based Confocal Laser-induced Endomicroscopy (pcle) 62. Cost-effectiveness Analysis of Wireless Capsule Motility (WCM) Compared to Traditional Testing for Patients with Functional Gastrointestinal Disorders 63. Chronic Electrical Stimulation at Acupuncture Points Improves Dyspeptic Symptoms in Patients with Diabetic Gastroparesis 64. Lymphoproliferative Disorders in Patients Receiving Thiopurines for Ulcerative Colitis: A Nationwide 10-Year Retrospective Cohort from the Veterans Affairs Healthcare System 65. Venous Thromboembolism Risk and Anti-Tumor-Necrosis Alpha Agents in Inflammatory Bowel Disease and Other Chronic Inflammatory Diseases 66. Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) 67. Predictors of Colorectal Neoplasia Outcomes in Indefinite and Low Grade Dysplasia in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis 68. Effects of Operation Iraqi Freedom and Operation Enduring Freedom on Inflammatory Bowel Disease Does Abdomino-Pelvic CT Done During Emergency Department Visit Affect Management in Patients with Inflammatory Bowel Diseases? vii